NICE ‘fast-tracking’ underlines threat from BMS/Pfizer’s Eliquis to Pradaxa and Xarelto
This article was originally published in Scrip
Executive Summary
The positive reimbursement decision from NICE on 23 January means that Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) means will likely start competing with Boehringer Ingelheim's Pradaxa (dabigatran etexilate) and Bayer's Xarelto (rivaroxaban) in stroke prevention as early as next month, February 2013. Datamonitor analyst Victoria Hudson, says Eliquis will compete well against its rival novel anticoagulants even in a market where uptake of warfarin-replacements has been slower than expected.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.